

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xunfei Healthcare Technology Co., Ltd.

訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2506)

**RESIGNATION OF BOARD SECRETARY,
JOINT COMPANY SECRETARY AND
AUTHORIZED REPRESENTATIVE AND
NON-COMPLIANCE WITH LISTING RULES**

The board of directors (the “**Board**”) of Xunfei Healthcare Technology Co., Ltd. (the “**Company**”) wishes to announce that Dr. Liu Wei (“**Dr. Liu**”) has tendered her resignation as the Board secretary, joint company secretary and the authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) due to change in work arrangements, with effect from July 24, 2026.

Dr. Liu has confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board would like to take this opportunity to express its sincere gratitude to Dr. Liu for her contributions to the Company during her tenure of service.

Following the resignation of Dr. Liu, the other joint company secretary of the Company, Ms. Yeung Siu Lam, who possesses the professional qualifications and relevant experience of a company secretary as required under Rule 3.28 of the Listing Rules, will remain in office and continue to act as the company secretary of the Company.

Following the resignation of Dr. Liu as the authorized representative, the Company is unable to comply with the requirement under Rule 3.05 of the Listing Rules that an issuer should appoint two authorized representatives. In view of this, the Company will, in compliance with the requirements of the Listing Rules, identify a suitable candidate to fill the vacancy of the authorized representative as soon as practicable and within three months, so as to ensure the Company's compliance with Rule 3.05 of the Listing Rules. The Company will make further announcement as and when appropriate.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, July 24, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.